Common use of Publications Clause in Contracts

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).

Publications. Pfizer shall not submit for publication or presentation(a) Subject to Mirati’s review and approval as set forth below, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Licensee shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates publish Clinical Data pertaining to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted the Compound or any Licensed Product and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under Licensee from Local Studies in the Licensed Territory pursuant to this Agreement without Pfizerand subject to this Section 12.3. Mirati shall have the right to review, comment on, and approve any material proposed for disclosure or publication by Licensee regarding any such Clinical Data or results of and other information regarding Licensee’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according Development activities with respect to the procedures set forth in this Section 14.3 Compound or any Licensed Product, whether by oral presentation, manuscript, or abstract. Before any such material is submitted for publication or presentation of Pfizer the same is made, Licensee shall deliver a complete copy to Mirati at least [***] prior to submitting the material to a publisher or initiating any other disclosure. Mirati shall review any such material and give its comments to Licensee within [***] of receipt of such material, which comments Licensee shall implement. With respect to oral presentation materials and abstracts, Mirati shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to Licensee with appropriate comments, if any, but in no event later than [***] from receipt. Licensee shall comply with Mirati’s request to delete references to its Confidential Information)Information in any such material and agrees to delay any submission for publication or other public disclosure for a period of up to an additional [***] for the purpose of preparing and filing appropriate patent applications. Licensee shall have no right to publish outside the Licensed Territory (including in any form or media that may be distributed outside the Licensed Territory) or with respect to any Clinical Data generated from any Global Study, in each case, without Mirati’s prior written consent.

Publications. Pfizer The Parties recognize the desirability of publishing the results of Development activities under this Agreement. Accordingly, Licensee shall not submit for publication or presentation, or publish or present, any academic, be permitted to publicly disclose in scientific or medical publication journals, reference publications or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical presentations the results of Development activities under this Agreement in accordance with this Section 6.5. Prior to making any such publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes disclosure, Licensee shall provide MedImmune with drafts of preserving the value of the Licensed Technology and determining whether any portion of the such proposed publication or presentation containing Pfizer’s Confidential Information should be modified disclosure, including as applicable proposed abstracts, manuscripts or deletedsummaries of presentations. Pfizer MedImmune shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * respond promptly through its designated representative and in any event no later than [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation presentation. Licensee agrees to allow a reasonable additional period to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of MedImmune in a manner consistent with Applicable Law and industry practices. In addition, Licensee shall give due regard to comments furnished by MedImmune and such comments shall not be unreasonably rejected; provided, however, that if any such abstract, manuscript or summary of presentations contains any AstraZeneca Product Reference that (a) is not supported by the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended approved labeling for the AstraZeneca Product or presents an additional [ * ] in the event Pfizer can, within [ * ] of receipt unbalanced view of the written copy, demonstrate reasonable need for such extension including AstraZeneca Product considering the approved labeling for the preparation and filing AstraZeneca Product as a whole or (b) contains projections of patent applicationsthe market potential of the AstraZeneca Product, Licensee shall correct or remove such AstraZeneca Product Reference or such projections, as applicable. Iterum will comply with standard academic practice regarding authorship Notwithstanding the foregoing, subject to any copyrights or intellectual property rights of Third Parties, Licensee’s publications may include reprints of scientific or medical journal articles or reference publications and recognition of contribution of other parties regarding the AstraZeneca Product that, in any publication governed by this Section 14.3each case, including International Committee follow FDA’s “Good Reprint Practices for the Distribution of Medical Journal Editors standards regarding authorship Articles and contributionsMedical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices” guidance. For clarity, Iterum The terms of this Section 6.5 shall be free applicable to publish and present all Developed IP generated by any Sublicensee of Licensee or on behalf any of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Affiliates.

Publications. Pfizer Except as provided in this Agreement, neither Party or its Affiliates shall publish or publicly disclose the results of any of the research and/or development activities conducted under this Agreement, without the prior written consent of the other Party, except that after the expiration of all Options, the foregoing shall not submit apply to Anacor for publication or presentationresults that relate to any Anacor Development Compounds, or to GSK for results that relate directly to any GSK Development Compounds. The Parties recognize that it may be useful or required to publish or presentpublicly disclose the results of development work on Products, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How and GSK (to the extent such Licensed Know-How is still Pfizer’s Confidential Informationand its Affiliates and Sublicensees) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum only shall be free to publish or publicly disclose such results, subject to the prior review by Anacor for patentability and present all Developed IP generated protection of its Confidential Information. GSK shall provide to Anacor at GSK’s earliest practical opportunity any proposed abstracts, manuscripts or summaries of presentations which cover the results of clinical development of any Product, for review and comment as to matters relating to its patents and Confidential Information. Anacor shall respond in writing promptly and in no event later than [***] after receipt of the proposed material, or within such reasonably shorter period as is required (and promptly communicated by GSK to Anacor) by the relevant publication deadline, with [***] THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION. comments on the proposed material, which GSK will consider in good faith but have no obligation to accept, or on behalf a specific statement of Iterum concern, based upon either the need to seek patent protection. In the event of concern, GSK agrees not to submit such publication or its Affiliates or Partners under this Agreement without Pfizer’s review or approval to make such presentation that contains such information until Anacor is given a reasonable period of time (unless this Agreement has been terminated not to exceed [***]) to seek patent protection for any material in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according which it believes is patentable or to resolve any other issues. This Section 9.6 shall cease to apply with respect to any Product upon the First Commercial Sale of such Product. Furthermore, with respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, such materials shall be subject to review under this Section 9.6 to the procedures set forth in this Section 14.3 for publication extent that GSK or presentation of Pfizer Confidential Information)Anacor (as the case may be) has the right to do so.

Publications. Pfizer The Parties recognize the desirability of publishing and publicly disclosing the results of and information regarding, activities under this Agreement. Accordingly, Lilly shall not submit be free to publicly disclose the results of and information regarding, activities under this Agreement, subject to prior review by ACI of any disclosure of ACI Confidential Information for issues of patentability and protection of such Confidential Information, in a manner consistent with Applicable Law and industry practices, as provided in this Section ‎9.7. Accordingly, prior to publishing or disclosing any ACI Confidential Information, Lilly shall provide ACI with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such Confidential Information at least thirty (30) days prior to submission for publication or presentation, or publish or present, . ACI shall respond promptly through its designated representative and in any academic, scientific or medical publication or presentation disclosing the Licensed Know-How event no later than fifteen (to the extent such Licensed Know-How is still Pfizer’s Confidential Information15) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies days after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation. If ACI requests a delay in publication or presentation, Lilly shall delay such submission or presentation for a period not to exceed ninety (90) days to permit filings for Patent protection and to otherwise address issues of Confidential Information or related competitive harm to the “Review Period”)reasonable satisfaction of ACI. Pfizer In addition, Lilly will give due regard to comments furnished by ACI and such comments shall provide its comments with respect to such publications not be unreasonably rejected. ACI shall not and presentations within [ * ] shall cause each of its receipt Affiliates and its and their licensees and Sublicensees not to, make any publications or public disclosures regarding the Licensed Compounds or Licensed Products or any Confidential Information of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement Lilly without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain PfizerLilly’s prior written consent before such publication or presentation according consent, except to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)extent expressly permitted hereunder. CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

Publications. Pfizer shall not submit for publication or presentation, or NT Pharma may publish or presentpresent data or results relating to Product in scientific journals with primary circulation in the Territory or at scientific conferences in the Territory, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (subject to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentreview, comment and approval by Pfenex as set forth in this Section 8.6, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld withheld, delayed or delayedconditioned. Written copies of such NT Pharma shall provide Pfenex with the opportunity to review any proposed publication abstract, manuscript or presentation required which discloses information relating to be submitted hereunder shall be submitted Product by delivering a copy thereof to Pfizer Pfenex no later less than [ * ] sixty (60) days (for publication in scientific journals) or thirty (30) days (for presentation at scientific conferences) before its intended submission for publication or presentation. Pfenex shall have thirty (30) days (for publication in scientific journals) or ten (10) days (for presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of at scientific conferences) from its receipt of any such written copyabstract, manuscript or presentation in which to notify NT Pharma in writing of its approval or any specific objections to the disclosure. The Review Period may be extended for an additional [ * ] in In the event Pfizer canthat Pfenex objects to the disclosure in writing within such thirty (30) or ten (10) day period, within [ * ] of receipt NT Pharma agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the written copyproposed disclosure, demonstrate reasonable need for such extension including and if the Parties are unable to agree, the matter shall be referred to the Executive Steering Committee. NT Pharma shall delete from the proposed disclosure any Confidential Information of Pfenex upon the request of Pfenex. NT Pharma shall delay any proposed disclosure to allow Pfenex sufficient time for the preparation drafting and filing of a patent applicationsapplication directed to any patentable subject matter identified by Pfenex in such proposed disclosure. Iterum will comply Once any such abstract or manuscript is accepted for publication, NT Pharma shall provide Pfenex with standard academic practice regarding authorship a copy of the final version of the manuscript or abstract. The Parties further agree that for the presentation at scientific publications and recognition of contribution of other parties in conferences, if the abstract, manuscript or presentation intended for a forthcoming scientific conference does not go beyond that previously approved by Pfenex, then it shall be exempted from further approval by Pfenex as provided under this paragraph. NT Pharma shall not be obligated to prepare any publication governed by translations under this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum 8.6 but shall be free provide to publish and present all Developed IP generated Pfenex any translations prepared by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)NT Pharma.

Publications. Pfizer LICENSOR agrees not to publish, present or otherwise disclose any Proprietary Information of LICENSEE. LICENSEE shall be furnished copies of any proposed disclosure, publication or presentation (including any modifications thereof which LICENSEE has not submit for yet reviewed) containing or referring to any LICENSED TECHNOLOGY or LICENSED PATENT RIGHTS at least [* * *] before submission of such proposed disclosure, publication or presentation. With regard specifically to modification(s) to a disclosure, or publish or present, any academic, scientific or medical publication or presentation disclosing that LICENSEE has already reviewed prior to such modification(s), LICENSOR agrees that any Proprietary Information of LICENSEE which has been identified in writing by LICENSEE shall be deleted from the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentdisclosure, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizerand LICENSOR shall send LICENSEE a statement verifying that this has been done along with a final copy including the revision. In no event shall LICENSEE’s Confidential Information should be modified review of any modification to a disclosure, publication or deletedpresentation exceed the original [* * *] review period unless LICENSEE requests delay for patent protection. Pfizer During its review period(s), LICENSEE shall have the right to approve such proposed publications if such Pfizer’s Confidential review the material for Proprietary Information relates of LICENSEE and to [ * ]assess the patentability of any invention described in the material. If LICENSEE decides that a patent application should be filed, such [ * ] = Certain confidential information contained in this documentthe disclosure, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted delayed an additional [* * *] or a shorter period of time if LICENSEE consents in writing, whichever is sooner. At LICENSEE’s written request, Proprietary Information of LICENSEE shall be deleted. For the avoidance of doubt, proposed disclosures from LICENSOR to Pfizer no later than [ * ] before submission VCU shall be deemed and treated as proposed disclosures for the purposes hereof. Although LICENSEE shall have the option not to include its name on any publication or presentation, at LICENSEE’s request, any disclosure, publication or presentation (the “Review Period”). Pfizer made by LICENSOR and relating to LICENSED TECHNOLOGY or LICENSED PATENT RIGHTS shall provide its comments acknowledge LICENSEE’s contribution thereto in accordance with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of customary scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)practice.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Arrowhead shall have the right to approve make publications regarding any Development or Commercialization of the Compound or Products conducted by or on behalf of Arrowhead (or its Affiliates, licensees or sublicensees, as applicable) in the Arrowhead Territory, subject to the prior approval of GSK; provided that (a) Arrowhead shall submit such proposed publications if such Pfizer’s Confidential Information relates publication to [ * ], such [ * GSK at least [***] in advance of the intended submission [***] = Certain confidential information contained in this documentCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, marked by bracketsMARKED BY BRACKETS, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amendedHAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation of such publication for GSK’s review; (b) to the “Review Period”). Pfizer shall provide its comments with respect extent GSK notifies Arrowhead of any specific, reasonable objections to such publications and presentations within [ * ] publication, based on concern regarding the specific disclosure of any Know-How or other Confidential Information of GSK (or any of its receipt Affiliates or Sublicensees), as applicable, Arrowhead will delete any such Know-How or other Confidential Information and, acting reasonably and in good faith, consider any other such objections, including whether it is necessary or advisable to delete any other information from such proposed publication; and (c) upon GSK’s request, Arrowhead shall delay any such publication or presentation as needed to preserve the patentability of any Know-How or other Confidential Information of GSK (or any of its Affiliates or Sublicensees); provided that GSK may elect to extend such written copy. The Review Period may be extended publication review period for up to an additional [ * [***] in the event Pfizer canif GSK reasonably requests such extension, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of any such patent applications. Iterum will comply Once any such publication is accepted for publication, Arrowhead shall provide GSK with standard academic practice regarding authorship a copy of scientific publications and recognition the final version of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributionssuch publication. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant Subject to Section 13.2 ‎13.7, notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt, GSK shall have the right to make any publications regarding the Development or by Iterum pursuant to Section 13.4Commercialization of the Compound or any Product in the GSK Territory as it chooses, in which case Iterum its sole discretion, without the approval of Arrowhead; provided that the rights of GSK and the obligations of Arrowhead, in each case, in clauses (a), (b) and (c) shall obtain Pfizer’s prior written consent before apply mutatis mutandis, respectively, to Arrowhead for such publication or presentation according rights and to the procedures set forth in this Section 14.3 GSK for publication or presentation of Pfizer Confidential Information)such obligations.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer FivePrime shall have the right to approve publish manuscripts, abstracts, presentations or other articles in scientific journals or at scientific conferences relating to any Licensed Product without obtaining the prior written consent of INBRX; provided, however, that (i) INBRX shall have the right to review and comment upon each such proposed publications if such Pfizer’s manuscript, abstract, *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. CONFIDENTIAL Execution Copy presentation or other article in which an INBRX employee is also named as an author, that contains any Confidential Information relates of INBRX, INBRX Collaboration Know-How, Joint Collaboration Know-How or INBRX Know-How and FivePrime shall consider such comments in good faith, and (ii) INBRX shall be noted, including at INBRX’s discretion, the name and, if applicable, logo of INBRX, on each such publication. In the event that either Party desires to [ * ]make a publication pursuant to this Section 8.6, such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 Party shall provide a copy of the Securities Act of 1933proposed publication (including abstracts, as amended. approval not or presentation to be unreasonably withheld a journal, editor, meeting, seminar or delayed. Written copies other third party) to the other Party for comment at least *** prior to submission of such proposed manuscript for publication; the object being to prevent either the endangerment of applications for the protection of property rights by premature publications detrimental to their novelty or the disclosure of Confidential Information. If, during the *** specified above the non-publishing Party notifies the other Party that a proposed publication or presentation required contains patentable subject matter which requires protection, the non-publishing Party may by written notice delay the publication for a period of time not to be submitted hereunder shall be submitted to Pfizer no later than [ exceed *** ] before submission for publication or presentation (from the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt date of such written copynotice to seek appropriate patent protection for any subject matter in such publication that it reasonably believes may be patentable. The Review Period may be extended for an additional [ * ] in publishing Party shall delete from the event Pfizer can, within [ * ] of receipt proposed publication prior to submission all Confidential Information of the written copy, demonstrate reasonable need for such extension including for non-publishing Party that the preparation non-publishing Party identifies in good faith and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall requests to be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)deleted.

Publications. Pfizer LICENSOR agrees not to publish, present or otherwise disclose any Proprietary Information of LICENSEE. LICENSEE shall be furnished copies of any proposed disclosure, publication or presentation (including any modifications thereof which LICENSEE has not submit for yet reviewed) containing or referring to any LICENSED TECHNOLOGY or LICENSED PATENT RIGHTS at least thirty (30) days before submission of such proposed disclosure, publication or presentation. With regard specifically to modification(s) to a disclosure, or publish or present, any academic, scientific or medical publication or presentation disclosing that LICENSEE has already reviewed prior to such modification(s), LICENSOR agrees that any Proprietary Information of LICENSEE which has been identified in writing by LICENSEE shall be deleted from the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentdisclosure, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizerand LICENSOR shall send LICENSEE a statement verifying that this has been done along with a final copy including the revision. In no event shall LICENSEE’s Confidential Information should be modified review of any modification to a disclosure, publication or deletedpresentation exceed the original 30 day review period unless LICENSEE requests delay for patent protection. Pfizer During its review period(s), LICENSEE shall have the right to approve such proposed publications if such Pfizer’s Confidential review the material for Proprietary Information relates of LICENSEE and to [ * ]assess the patentability of any invention described in the material. If LICENSEE decides that a patent application should be filed, such [ * ] = Certain confidential information contained in this documentthe disclosure, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted delayed an additional sixty (60) days or a shorter period of time if LICENSEE consents in writing, whichever is sooner. At LICENSEE’s written request, Proprietary Information of LICENSEE shall be deleted. For the avoidance of doubt, proposed disclosures from LICENSOR to Pfizer no later than [ * ] before submission VCU shall be deemed and treated as proposed disclosures for the purposes hereof. Although LICENSEE shall have the option not to include its name on any publication or presentation, at LICENSEE’s request, any disclosure, publication or presentation (the “Review Period”). Pfizer made by LICENSOR and relating to LICENSED TECHNOLOGY or LICENSED PATENT RIGHTS shall provide its comments acknowledge LICENSEE’s contribution thereto in accordance with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of customary scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)practice.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academic, scientific or medical publication or presentation disclosing results of the Licensed Know-How (Research Program to the extent such Licensed Knowresults refer to, derive from or otherwise relate to (a) in cases where CytomX is ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. the Publishing Party, the ImmunoGen Technology, (b) in cases where ImmunoGen is the Publishing Party, the CytomX Technology, and (c) in cases where either Party is the Publishing Party, the Joint Program Technology, the Agreement PDCs or the ImmunoGen Probodies (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that (i) it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayeddisseminate Covered Results relating to CytomX Agreement PDCs prior to the publication or dissemination of such Covered Results by CytomX, and (ii) it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or disseminate Covered Results relating to ImmunoGen Probodies and ImmunoGen Agreement PDCs prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information. Such In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed CytomX Technology and ImmunoGen Technology and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] sixty (60) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of thirty (30) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] thirty (30) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer 16.3.1 Regeneron shall not submit for publication have the exclusive right to publish or presentationpublicly disclose the results of, or publish or presentinformation regarding, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (activities conducted with respect to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During Product in the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation Territory except that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer ZLAB shall have the right to approve publish the results of clinical trials performed pursuant to the Territory Development Plan and, to the extent such proposed publications if such Pfizer’s Confidential Information relates results have already been published by Regeneron, the results of clinical trials performed pursuant to [ * ]the GT Operational Plan, such [ * ] = Certain confidential information contained in this documenteach case, marked by brackets, has been omitted and filed separately with the Securities prior written approval of Regeneron in accordance with this Section 16.3. If Regeneron desires to publish or publicly disclose the results of, or information regarding, activities conducted with respect to the Product in the Territory, ZLAB shall cooperate fully with Regeneron and Exchange Commission shall provide such assistance as is reasonably requested by Regeneron with respect thereto, including with respect to any application or approval necessary in the Territory. If ZLAB desires to publish the results of a clinical trial performed pursuant to Rule 406 the Territory Development Plan or GT Operational Plan (to the extent set forth in the first sentence of the Securities Act of 1933this Section 16.3.1), as amended. approval not to be unreasonably withheld or delayed. Written copies ZLAB shall provide Regeneron with a draft of such proposed abstract, manuscript or summary of presentation that covers such results at least […***…] prior to submission or disclosure, as applicable, for Regeneron’s approval. ZLAB shall incorporate any reasonable comments of Regeneron with respect thereto. If Regeneron informs ZLAB that such proposed abstract, manuscript or summary of presentation, in Regeneron’s reasonable judgment, could be expected to have an adverse effect on any patentable invention owned by or licensed to, in whole or in part, Regeneron, or could be expected to disclose any Information that is Confidential Information of Regeneron, ZLAB shall delay or prevent such publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation as follows: (the “Review Period”). Pfizer shall provide its comments a) with respect to a patentable invention, such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may publication shall be extended for an additional [ * ] in delayed sufficiently long (not to exceed […***…]) to permit the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the timely preparation and filing of a patent applications. Iterum will comply application; and (b) with standard academic practice regarding authorship respect to Information that is Confidential Information of scientific publications and recognition of contribution of other parties in any Regeneron, such Information shall be deleted from the publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributionsupon Regeneron’s request. For clarity, Iterum ZLAB shall be free to not publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according public disclosure with respect to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Product that has not been approved by Regeneron].

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum each Party shall submit to Pfizer the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains Pfizerthe Non-Disclosing Party’s Confidential Information. Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program, provided that Pfizer shall not be required to submit any proposed publication or public presentation to CytomX for review and approval pursuant to this sentence to the extent such publication or presentation relates to any Research Project Target for which Pfizer has exercised its Option pursuant to this Agreement and to the extent consistent with Pfizer’s normal and customary publication practices. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and PDC Developed IP and the rights granted to Pfizer hereunder and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve Written copies of such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = ***Certain confidential information contained in this document, marked by brackets, herein has been omitted and filed separately with the Securities and Exchange Commission pursuant Commission. Confidential treatment has been requested with respect to Rule 406 of the Securities Act of 1933, as amendedomitted portions. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of twenty (20) days after its receipt of such written copy, and the other Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum CytomX and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)7.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed Know-How is still Pfizer’s Confidential Information) Intellectual Property (the “Covered Results”), without Iterum’s the prior written consentreview by and approval of the other Party (in such capacity, such consent the “Non‑Disclosing Party”), which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayed. During disseminate Covered Results prior to the Term, Iterum publication or dissemination of such Covered Results by CytomX. The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to CytomX only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of ImmunoGen [***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Such Confidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested by CytomX Therapeutics, Inc. (including, without limitation, any nonpublic Licensed Intellectual Property). In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of fifteen (15) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or delayeddisseminate Covered Results prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to ImmunoGen only to the extent any such proposed ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Such Confidential treatment has been requested with respect to the omitted portions. publication or presentation would refer to, describe or otherwise disclose Confidential Information of CytomX (including, without limitation, any non-public Licensed Intellectual Property). In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayed. During disseminate Covered Results prior to the Term, Iterum publication or dissemination of such Covered Results by CytomX. The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to CytomX only to the extent any such proposed ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Such Confidential treatment has been requested with respect to the omitted portions. publication or presentation would refer to, describe or otherwise disclose Confidential Information of ImmunoGen (including, without limitation, any non-public Licensed Intellectual Property). In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer shall not submit for Allergan recognizes that the publication or presentationof papers regarding results of and other Information regarding activities under this Agreement by Licensee, or publish or presentincluding oral presentations and abstracts, any academicmay be beneficial to both Parties, scientific or medical publication or presentation disclosing the Licensed Know-How (provided that such publications are subject to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not reasonable controls to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s protect Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Accordingly, Allergan shall at all times have the right to review and approve any paper proposed for publication by Licensee, including any oral presentation or abstract, that contains Confidential Information of Allergan. Before any such proposed publications paper is submitted for publication or an oral presentation is made, Licensee shall deliver a complete copy of the paper or materials for oral presentation to Allergan at least [***] prior to submitting the paper to a publisher or making the presentation. Allergan shall review any such paper and give its comments to Licensee, and if applicable, notify Licensee whether Allergan approves of such Pfizerpaper, in each case within [***] after the delivery of such paper to Allergan. With respect to oral presentation materials and abstracts, Allergan shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to Licensee with appropriate comments, if any, but in no event later than [***] after the date of delivery to Allergan. Failure to respond within such [***] shall be deemed approval to publish or present. Notwithstanding the foregoing, Licensee shall comply with Allergan’s written request to (i) delete references to Allergan’s Confidential Information relates to [ * ], in any such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication paper or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for or (ii) withhold publication of any such paper or any presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended same for an additional [ * [***] in the event Pfizer can, within [ * ] of receipt order to permit Allergan to obtain patent protection if Allergan deems it necessary. Any publication shall include recognition of the written copycontributions of Allergan according to standard practice for assigning scientific credit, demonstrate either through authorship or acknowledgement, as may be appropriate. Licensee shall use commercially reasonable need for such extension including efforts to cause investigators and institutions participating in Clinical Trials for the preparation and filing of patent applications. Iterum will comply Licensed Products in the Field with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free which it contracts to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant agree to Section 13.2 or by Iterum pursuant terms substantially similar to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures those set forth in this Section 14.3 for publication 7.5, which efforts shall satisfy Licensee’s obligations under this Section 7.5 with respect to such investigators and institutions. Allergan shall not publish any paper regarding the Licensed Compound or presentation of Pfizer Confidential Information)any Licensed Product in the Field, including oral presentations and abstracts, without Licensee’s prior written consent.

Publications. Pfizer Following the Amended Effective Date, Arrowhead shall not submit for publication have the right to make any publications regarding the Development or presentationCommercialization of any Licensed Construct or Licensed Product in the Territory, including to publish any results of any Clinical Trial or publish other Development activities conducted with respect to any Licensed Construct or presentLicensed Product, any academicin each case, scientific or medical publication or presentation disclosing without the Licensed Know-How (prior approval of GSK. Notwithstanding anything to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentcontrary in this Agreement, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes avoidance of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer doubt, GSK shall have the right to approve such proposed make any publications if such Pfizer’s regarding the Development or Commercialization of any Licensed Construct or Licensed Product in the Territory as it chooses, in its sole discretion, without the approval of Arrowhead, including any Confidential Information relates as reasonably required for GSK’ s compliance with its then- current policy on the registration and reporting of results of pharmaceutical company- sponsored Clinical Trials including disclosures made by GSK on xxxxxxxxxxxxxx.xxx; provided that (a) GSK shall submit such publication to [ * ], such [ * Arrowhead at least [***] = Certain confidential information contained Business Days in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 advance of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before intended submission for publication or presentation of such publication for Arrowhead’s review; (b) to the “Review Period”). Pfizer shall provide its comments with respect extent Arrowhead notifies GSK of any specific, reasonable objections to such publications and presentations publication within [ * [***] Business Days following GSK submitting such publication to Arrowhead for review pursuant to the foregoing clause (a), based on concern regarding the specific disclosure of any Confidential Information of Arrowhead (or any of its receipt Affiliates), as applicable, GSK will delete any such Confidential Information and, acting reasonably and in good faith, consider any other such objections, including whether it is necessary or advisable to delete any other information from such proposed publication; and (c) upon Arrowhead’s request, GSK shall delay any such publication or presentation as needed to preserve the patentability of any Confidential Information of Arrowhead (or any of its Affiliates); provided, further, that Arrowhead may elect, by delivery of written notice to GSK, to extend such written copy. The Review Period may be extended publication review period for up to an additional [ * [***] in Business Days solely to the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for extent necessary to permit the preparation and filing of any such patent applications. Iterum will comply applications with standard academic practice regarding authorship respect to such Confidential Information of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum Arrowhead (or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated Affiliates), as applicable. Arrowhead agrees to provide, and to cause its applicable subcontractors to provide, to GSK such assistance as reasonably requested in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before connection with fulfilling the requirements of such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)policy.

Publications. Pfizer shall not submit Actinium acknowledge that it is Site's policy that the results of the Study must be publishable and the Investigator and others employed by Site or who are engaged in the Study be permitted to present at symposia, national or regional professional meetings and to publish in journals, theses or dissertations or otherwise in their sole discretion, the methods and results of the Study. The parties recognize that because this is a multi-center Study, there is a need for a coordinated approach to any publication or public disclosure of the data or results of this Study. To that end, there will be no publication or public disclosure of such data or results by the Site or Investigator until a multi-center publication is submitted for publication or presentationpresentation by Actinium, or its designee. However, if no multi-site publication is submitted by Actinium or its designee within twelve (12) months of the completion termination, or abandonment of the Study from all sites, the Site and the Investigator shall be free to publish for non-commercial purposes the Study results from there Site as follows. If the Site or the Investigator wishes to publish or present, publicly disclose Study and data or results the Site will submit any academic, scientific proposed manuscript or medical publication to Actinium for comment at least thirty (30) days prior to its submission for publication or presentation disclosing other disclosure. The Site will review and consider in good faith comments received from Actinium during such thirty (30) day period. If requested to do so by Actinium, Site agrees to remove confidential information provided by Actinium prior to submitting the Licensed Know-How manuscript or publication, excluding Study data / results or any other information that may be required by the publishing source. Actinium will make every reasonable attempt to notify the Site within said thirty (to the extent such Licensed Know-How is still Pfizer’s Confidential Information30) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes days of preserving the value of the Licensed Technology and determining whether any portion receipt of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deletedwhether it is desirable to file a patent application on any inventions contained in the proposed publication. Pfizer In the event Actinium decides to pursue patent protection, Actinium shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed defer publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in thirty (30) days to permit the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of any desired patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)application.

Publications. Pfizer The Parties recognize the desirability of publishing the results of Development activities under this Agreement. Accordingly, Licensee shall not submit for publication or presentation, or publish or present, any academic, be permitted to publicly disclose in scientific or medical publication journals, reference publications or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical presentations the results of Development activities performed by Licensee or Licensor under this Agreement in accordance with this Section 7.5. Prior to making any such publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes disclosure, Licensee shall provide Licensor with drafts of preserving the value of the Licensed Technology and determining whether any portion of the such proposed publication or presentation containing Pfizer’s Confidential Information should be modified disclosure, including as applicable proposed abstracts, manuscripts or deletedsummaries of presentations. Pfizer Licensor shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained respond promptly through its designated representative and in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies any event no later than thirty (30) days after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation presentation. Licensee agrees to allow a reasonable additional period to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of Licensor in a manner consistent with Applicable Law and industry practices. In addition, Licensee shall give due regard to comments furnished by Licensor and such comments shall not be unreasonably rejected; provided, however, that if any such abstract, manuscript or summary of presentations contains any AstraZeneca Product Reference that (a) is not supported by the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended approved labeling for the AstraZeneca Product or presents an additional [ * ] in the event Pfizer can, within [ * ] of receipt unbalanced view of the written copy, demonstrate reasonable need for such extension including AstraZeneca Product considering the approved labeling for the preparation and filing AstraZeneca Product as a whole or (b) contains projections of patent applicationsthe market potential of the AstraZeneca Product, Licensee shall correct or remove such AstraZeneca Product Reference or such projections, as applicable. Iterum will comply with standard academic practice regarding authorship Notwithstanding the foregoing, subject to any copyrights or intellectual property rights of Third Parties, Licensee’s publications may include reprints of scientific or medical journal articles or reference publications and recognition of contribution of other parties regarding the AstraZeneca Product that, in any publication governed by this Section 14.3each case, including International Committee follow FDA’s “Good Reprint Practices for the Distribution of Medical Journal Editors standards regarding authorship Articles and contributionsMedical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices” guidance or an equivalent regulatory guidance in the Territory. For clarity, Iterum The terms of this Section 7.5 shall be free applicable to publish and present all Developed IP generated by any Sublicensee of Licensee or on behalf any of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Affiliates.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation The Parties recognize the desirability of publishing and publicly disclosing the Licensed Know-How (results of and information regarding, activities under this Agreement. Accordingly, Licensee shall be free to publicly disclose the extent such Licensed Know-How is still Pfizerresults of and information regarding, activities under this Agreement, subject to prior review by AstraZeneca of any disclosure of AstraZeneca’s Confidential Information for issues of patentability and protection of such Confidential Information, in a manner consistent with Applicable Law and industry practices, as CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD. HAS DETERMINED THE INFORMATION (I) without Iterum’s IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO DERMAVANT SCIENCES LTD. IF PUBLICLY DISCLOSED. provided in this Section 6.5 (Publications). Accordingly, prior written consentto publishing or disclosing any Confidential Information of AstraZeneca, Licensee shall provide AstraZeneca with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology AstraZeneca shall respond promptly through its designated representative and determining whether in any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * event no later than [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation presentation. Licensee agrees to allow a reasonable period (not to exceed [***]) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the “Review Period”)reasonable satisfaction of AstraZeneca. Pfizer In addition, Licensee shall provide its give due regard to comments with respect to furnished by AstraZeneca and such publications and presentations within [ * ] of its receipt of such written copycomments shall not be unreasonably rejected. The Review Period may be extended for an additional [ * ] in In the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free that AstraZeneca desires to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement AstraZeneca Know-How, AstraZeneca shall not submit any publications relating to the AstraZeneca Know-How without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain PfizerLicensee’s prior written consent before such publication or presentation according not to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)be unreasonable withheld.

Publications. Pfizer shall not submit for publication or presentation, or Recipient may publish or present, any academic, scientific or medical otherwise publicly disclose the results of the work with the Material. Prior to publication or presentation disclosing of any results using the Licensed Know-How (to Material, the extent Recipient will provide WHO with a copy of such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical intended publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value ensuring that it contains no disclosure of the Licensed Technology and determining whether any portion of the proposed confidential and/or proprietary Information. Any objection to publication or presentation containing Pfizer’s Confidential Information should for the aforesaid reason will be modified or deleted. Pfizer shall have notified by WHO to the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 Recipient within a period of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for publication or presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] sixty days of receipt of the written draft copy. In the absence of such an objection within that sixty-day period, demonstrate reasonable need for the publication or presentation may proceed. Recipient agrees to provide WHO with 5 free copies of any such extension including for the preparation and filing of patent applicationspublications or presentations. Iterum will comply with standard academic practice regarding authorship of scientific All such intended publications and recognition presentations of contribution the results using the Material will contain an acknowledgement of other parties in WHO, the WHO/TDR TB Specimen Bank and any publication governed contributors thereto as indicated by this Section 14.3WHO and include a reference to the WHO/TDR specimen catalogue numbers. The Recipient agrees to consult WHO with regard to giving appropriate acknowledgement as aforesaid, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication is published or presentation according is made. Confidentiality Obligations of WHO Any information provided by the Recipient to WHO under, or in connection with, the Material Request Form, will - if marked 'confidential' - be treated by WHO as confidential and proprietary to the procedures set forth Recipient, for a period of five years after the disclosure of such information to WHO. In this connection, WHO will only use and disclose such information for the purpose of evaluating such information and determining (in this Section 14.3 WHO's sole discretion) the merit of releasing Material for publication Research, Development, Testing and/or Evaluation activities by the Recipient. However, there will be no obligations of confidentiality and restrictions on use, to the extent that WHO is clearly able to demonstrate that the aforementioned information or presentation any part thereof: was known to WHO prior to their disclosure by the Recipient hereunder; or has been independently devised, or arrived at, by or for WHO without access to the disclosure made by the Recipient hereunder; or was in the public domain at the time of Pfizer Confidential Information)disclosure hereunder, or becomes part of the public domain through no fault of WHO; or becomes available to WHO from a third party, who is not in breach of any obligations of confidentiality owed to the Recipient.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum each Party shall submit to the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s Confidential Information. In addition, Company shall submit to Pfizer for review and approval any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Informationrelating to this Agreement. Such In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Company Intellectual Property and the rights granted to Pfizer hereunder and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of its receipt of such written copy. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum Company and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.36.5.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For the sake of clarity, Iterum shall be free Pfizer’s obligation to publish submit any publication to Company for review and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners approval under this Agreement without PfizerSection 6.5.2 shall not apply to any publication which does not contain Company’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information).. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. EXECUTION VERSION

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Verastem shall have the right to approve publicly present or publish any Clinical Trial data, non-clinical data or any associated results or conclusions generated pursuant to this Agreement (each such proposed publications if presentation or publication, a “Publication”), provided that such Pfizer’s presentation or publication shall not include any Confidential Information relates of Licensee without Licensee’s prior written consent. Licensee shall not have the right to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately issue any Publication except with the Securities prior written approval of Verastem and Exchange Commission pursuant in accordance with Verastem's Global Strategy. If Licensee desires to Rule 406 publicly present or publish a Publication in accordance with the foregoing sentence, then Licensee shall provide Verastem (including the Alliance Manager and all Verastem members of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies JSC) with a copy of such proposed publication Publication at least [* * *] days prior to the earlier of its presentation or presentation required intended submission for publication, or if Licensee has fewer than [* * *] days before submitting such proposed Publication for the reasons of authors, Licensee shall provide Verastem (including the Alliance Manager and all Verastem members of the JSC) with a copy of such proposed Publication as soon as reasonably practicable. Licensee agrees that it will not submit or present any Publication until Verastem has approved such Publication in writing. Licensee shall incorporate any reasonable written comments received from Verastem, including (i) the deletion of any Confidential Information of Verastem that Verastem identifies for deletion in Verastem’s written comments, and (ii) the deletion of any Clinical Trial data, results, conclusions or other related information which Verastem determines, in its sole discretion, to be submitted hereunder THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (“SEC”). REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SEC. conflict with Verastem’s Global Strategy with respect to the Licensed Product. If permitted to publish or present any Publication pursuant to this Section ‎8.4 Licensee shall be submitted to Pfizer no later than [ * ] before provide Verastem a copy of the Publication at the time of the submission for publication or presentation (presentation. Licensee agrees to acknowledge the “Review Period”)contributions of Verastem, and the employees of Verastem, in all Publications as scientifically appropriate. Pfizer Licensee shall provide require its comments with respect Affiliates, Sublicensees and Subcontractors to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship the obligations of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3‎8.4 as if they were Licensee, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 liable for publication or presentation of Pfizer Confidential Information)their non-compliance.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. withheld; provided that it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayed. During disseminate Covered Results prior to the Term, Iterum publication or dissemination of such Covered Results by CytomX. The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to CytomX only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of ImmunoGen (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayed. During disseminate Covered Results prior to the Term, Iterum publication or dissemination of such Covered Results by CytomX. The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to CytomX only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of ImmunoGen (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of fifteen (15) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer Notwithstanding anything to the contrary in this Agreement, (a) prior to Alnylam’s exercise of the Alnylam Commercialization Option for a particular Product pursuant to Section 4.3 and after Alnylam declines to exercise the Alnylam Commercialization Option for such Product, Dicerna shall not submit have the sole right to publish the results of the Development activities with respect to such Product, subject to the process described below; and (b) after Alnylam’s exercise of the Alnylam Commercialization Option for a particular Product, the Parties shall, through JCC, coordinate and determine publication of the results of the Development activities with respect to such Product. In the event that Dicerna desires to make any publication or public presentation relating to a Product under clause (a) above and such publication or presentation contains Alnylam’s Confidential Information, Dicerna shall deliver to Alnylam a copy of the proposed written publication or presentation at least [* * *] days prior to || submission for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer Alnylam shall have the right (i) to approve such proposed publications if such Pfizer’s Confidential Information relates propose modifications to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation for patent reasons, trade secret reasons or business reasons, which proposals Dicerna may accept or reject in its discretion (except that Dicerna shall be required to be submitted hereunder shall be submitted remove any Confidential Information of Alnylam at Alnylam’s request), and (ii) to Pfizer no later than [ * ] before submission for request a reasonable delay in publication or presentation in order to protect patentable information in accordance with Article 8. If Alnylam requests a delay pursuant to clause (the “Review Period”ii), Dicerna shall delay submission or presentation for up to a [* * *] additional days to enable Alnylam to file patent applications protecting Alnylam’s rights in such information in accordance with Article 8. Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The Review Period may be extended for an additional [ * ] In any scientific publication in the event Pfizer canscientific literature (journal article, within [ * ] of receipt of book chapter, poster) referencing data created or generated by Alnylam related to the written copyProducts, demonstrate reasonable need for such extension including Dicerna shall endeavor to include appropriate acknowledgements, consistent with the Recommendations for the preparation Conduct, Reporting, Editing, and filing Publication of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties Scholarly Work in any publication governed Medical Journals published by this Section 14.3, including the International Committee of Medical Journal Editors standards regarding authorship Editors, of the related roles and contributions. For clarity, Iterum shall be free to publish contributions of Alnylam and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)entities’ respective individual involved scientists.

Publications. Pfizer After the Termination Effective Date, GSK shall not publish, present publicly, or submit for written or oral publication any manuscript, abstract presentation or the like that includes Transferred GSK Know-How other than those publications set forth on Schedule 4.3C attached hereto (“Permitted GSK Publications”). Prior to GSK publishing, publicly presenting and/or submitting for written or oral publication any Permitted GSK Publications, GSK shall provide XenoPort a copy thereof for review at least [… * …] in advance (unless GSK is required by Applicable Laws or GSK’s Applicable Policies and Procedures to publish such information sooner, in which event GSK shall provide a copy for review as far in advance as practicable). GSK shall consider in good faith, but shall in no event be obligated to incorporate, any comments provided by XenoPort during such [… * …] period. In the event that XenoPort fails to provide any comments during such [… * …] period (or such shorter period if required under Applicable Laws), XenoPort shall be deemed to have no comments to such Permitted GSK Publication. In addition, GSK shall, at the request of XenoPort within such [… * …]period, remove any Confidential Information of XenoPort therefrom, except GSK shall have the right to publicly disclose any information, including Confidential Information, pertaining to safety of Product that GSK reasonably believes in good faith it is obligated to disclose to comply with Applicable Laws or GSK’s Applicable Policies and Procedures. During the Transition Period, XenoPort may submit for publication a manuscript, abstract or presentation, the like in the Territory that includes data or publish other information relating to Compound or present, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (to the extent such Licensed Know-How is still PfizerProduct only with GSK’s Confidential Information) without Iterum’s prior written consent, such consent not to be unreasonably withheld (provided that such manuscript, abstract or delayedlike would not be published until after the Transition Period End Date), and after the Transition Period End Date, XenoPort may publish, publicly present or submit for publication a manuscript, abstract or the like that includes data or other information relating to Compound or Product. During For the Termavoidance of doubt, Iterum XenoPort may at any time submit for publication a manuscript, abstract or the like outside the Territory that includes data or other * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXECUTION COPY information relating to Compound or Product, but for any such publication a manuscript, abstract or the like submitted prior to the Transition Period End Date shall submit provide GSK a copy thereof for its clinical review for at least [… * …] (unless XenoPort is required by Applicable Laws to Pfizer for review publish such information sooner), and shall consider in good faith any proposed academiccomments provided by GSK during such [… * …] period. In the event that GSK fails to provide any comments during such [… * …] period (or such shorter period if required under Applicable Laws), scientific or medical publication or public presentation that contains Pfizer’s Confidential InformationGSK shall be deemed to have no comments thereto. Such review will be conducted for In addition, XenoPort shall, at the purposes request of preserving the value of the Licensed Technology and determining whether GSK within such [… * …] period, remove any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer of GSK therefrom, except XenoPort shall have the right to approve such proposed publications if such Pfizer’s publicly disclose any information, including Confidential Information relates Information, pertaining to [ * ], such [ * ] = Certain confidential information contained safety of Product that XenoPort reasonably believes in this document, marked by brackets, has been omitted and filed separately good faith it is obligated to disclose to comply with the Securities and Exchange Commission pursuant to Rule 406 Applicable Laws. The contribution of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder each Party shall be submitted noted in all publications or presentations by acknowledgment or co-authorship, whichever is appropriate. Further, nothing herein shall be deemed as preventing GSK or any of its Affiliates from publishing data or other information relating to Pfizer no later than [ * ] before submission for publication the Compound or presentation (the “Review Period”). Pfizer shall provide its comments Product, or relating to RLS, PHN or any related medical condition, that is publicly known or that was generated independently of GSK’s program with respect to such publications the Compound or Product prior to the Termination Effective Date and presentations within [ * ] independently of its receipt of such written copy. The Review Period may be extended for an additional [ * ] in GSK’s activities with respect to the event Pfizer canCompound or Product under this Termination Agreement (including the Ongoing Studies), within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3manuscript, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by abstract or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)like.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for CytomX to withhold its consent to any request by ImmunoGen to publish or delayed. During disseminate Covered Results prior to the Term, Iterum publication or dissemination of such Covered Results by CytomX. The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to CytomX only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of ImmunoGen (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = ***Certain confidential information contained in this document, marked by brackets, herein has been omitted and filed separately with the Securities and Exchange Commission pursuant Commission. Confidential treatment has been requested with respect to Rule 406 of the Securities Act of 1933, as amendedomitted portions. approval not to Non-Disclosing Party’s Confidential Information should be unreasonably withheld modified or delayeddeleted. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer shall not submit for publication or presentation, or publish or present, any academic, scientific or medical publication or presentation The Parties recognize the desirability of publishing and publicly disclosing the Licensed Know-How (results of and information regarding, activities under this Agreement. Accordingly, Licensee shall be free to publicly disclose the extent such Licensed Know-How is still Pfizerresults of and information regarding, activities under this Agreement, subject to prior review by AstraZeneca of any disclosure of AstraZeneca’s Confidential Information for issues of patentability and protection of such Confidential Information) without Iterum’s , in a manner consistent with Applicable Law and industry practices, as [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. provided in this Section 6.5 (Publications). Accordingly, prior written consentto publishing or disclosing any Confidential Information of AstraZeneca, Licensee shall provide AstraZeneca with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology AstraZeneca shall respond promptly through its designated representative and determining whether in any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * event no later than [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies after receipt of such proposed publication or presentation or such shorter period as may be required to be submitted hereunder shall be submitted to Pfizer no later than [ * ] before submission for by the publication or presentation presentation. Licensee agrees to allow a reasonable period (not to exceed [***]) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the “Review Period”)reasonable satisfaction of AstraZeneca. Pfizer In addition, Licensee shall provide its give due regard to comments with respect to furnished by AstraZeneca and such publications and presentations within [ * ] of its receipt of such written copycomments shall not be unreasonably rejected. The Review Period may be extended for an additional [ * ] in In the event Pfizer can, within [ * ] of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Iterum will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free that AstraZeneca desires to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement AstraZeneca Know-How, AstraZeneca shall not submit any publications relating to the AstraZeneca Know-How without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain PfizerLicensee’s prior written consent before such publication or presentation according not to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)be unreasonable withheld.

Publications. Pfizer shall not submit for publication or presentation, or NT Pharma may publish or presentpresent data or results relating to Product in scientific journals with primary circulation in the Territory or at scientific conferences in the Territory, any academic, scientific or medical publication or presentation disclosing the Licensed Know-How (subject to the extent such Licensed Know-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentreview, comment, and approval by the Licensor as set forth in this Clause 8.9, such consent not to be unreasonably withheld or delayed. During the Term, Iterum shall submit to Pfizer for review any proposed academic, scientific or medical publication or public presentation that contains Pfizer’s Confidential Information. Such review will be conducted for the purposes of preserving the value of the Licensed Technology and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld withheld, delayed or delayedconditioned. Written copies of such NT Pharma shall provide the Licensor with the opportunity to review any proposed publication abstract, manuscript or presentation required which discloses information relating to be submitted hereunder shall be submitted Product by delivering a copy thereof to Pfizer the Licensor no later less than [ * ] sixty (60) days (for publication in scientific journals) or thirty (30) days (for presentation at scientific conferences) before its intended submission for publication or presentation. The Licensor shall have thirty (30) days (for publication in scientific journals) or ten (10) days (for presentation (the “Review Period”). Pfizer shall provide its comments with respect to such publications and presentations within [ * ] of at scientific conferences) from its receipt of any such written copyabstract, manuscript or presentation in which to notify NT Pharma in writing of its approval or any specific objections to the disclosure. The Review Period may be extended for an additional [ * ] in In the event Pfizer canthat the Licensor objects to the disclosure in writing within such thirty (30) or ten (10) day period, within [ * ] of receipt NT Pharma agrees not to submit the publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the written copyproposed disclosure, demonstrate reasonable need for such extension including and if the Parties are unable to agree, the matter shall be referred to the Executive Steering Committee. NT Pharma shall delete from the proposed disclosure any Confidential Information of the Licensor upon the request of the Licensor. NT Pharma shall delay any proposed disclosure to allow the Licensor sufficient time for the preparation drafting and filing of a patent applicationsapplication directed to any patentable subject matter identified by the Licensor in such proposed disclosure. Iterum will comply Once any such abstract or manuscript is accepted for publication, NT Pharma shall provide the Licensor with standard academic practice regarding authorship a copy of the definitive version of the manuscript or abstract. The Parties further agree that for the presentation at scientific publications and recognition of contribution of other parties in any publication governed conferences, if the abstract, manuscript or presentation intended for a forthcoming scientific conference does not go beyond that previously approved by this Section 14.3the Licensor, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum then it shall be free to publish and present all Developed IP generated exempted from further approval by or on behalf of Iterum or its Affiliates or Partners the Licensor as provided under this Agreement without Pfizer’s review or approval (unless paragraph. NT Pharma shall not be obligated to prepare any translations under this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum Clause 8.9 but shall obtain Pfizer’s prior written consent before such publication or presentation according provide to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)Licensor any translations prepared by NT Pharma.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or delayeddisseminate Covered Results prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to ImmunoGen only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of CytomX (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * [***] before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * [***] of after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * [***] in the event Pfizer the Non-Disclosing Party can, within [ * [***] of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.

Publications. Pfizer The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party (in such capacity the “Publishing Party”) agrees that, except as required by Applicable Laws, it shall not submit for publication or presentation, or publish or present, or permit to be published or presented, any academicresults of the Development, scientific Manufacture, use or medical publication or presentation disclosing the Commercialization of a Licensed Know-How (Product to the extent such results refer to, derive from or otherwise relate to the Licensed KnowIntellectual Property (the “Covered Results”), without the prior review by and approval of the other Party (in such capacity, the “Non-How is still Pfizer’s Confidential Information) without Iterum’s prior written consentDisclosing Party”), such consent which approval shall not to be unreasonably withheld withheld; provided that it shall not be deemed unreasonable for ImmunoGen to withhold its consent to any request by CytomX to publish or delayeddisseminate Covered Results prior to the publication or dissemination of such Covered Results by ImmunoGen. During the Term, Iterum The Publishing Party shall submit to Pfizer the Non-Disclosing Party for review and approval any proposed academic, scientific or and medical publication or public presentation that which contains PfizerCovered Results or otherwise contains the Non-Disclosing Party’s Confidential Information; provided that the foregoing requirement shall apply to ImmunoGen only to the extent any such proposed publication or presentation would refer to, describe or otherwise disclose Confidential Information of CytomX (including, without limitation, any non-public Licensed Intellectual Property). Such In addition, each Party shall submit to the other Party for review and approval any proposed publication or public ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. presentation relating to data generated under the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Technology Intellectual Property and determining whether any portion of the proposed publication or presentation containing Pfizerthe Non-Disclosing Party’s Confidential Information should be modified or deleted. Pfizer shall have the right to approve such proposed publications if such Pfizer’s Confidential Information relates to [ * ], such [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. approval not to be unreasonably withheld or delayed. Written copies of such proposed publication or presentation required to be submitted hereunder shall be submitted to Pfizer the Non-Disclosing Party no later than [ * ] thirty (30) days before submission for publication or presentation (the “Review Period”). Pfizer The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within [ * ] of fifteen (15) days after its receipt of such written copy, and the Publishing Party shall delete any Confidential Information of the Non-Disclosing Party upon request. The Review Period may be extended for an additional [ * ] sixty (60) days in the event Pfizer the Non-Disclosing Party can, within [ * ] fifteen (15) days of receipt of the written copy, demonstrate reasonable need for such extension extension, including for the preparation and filing of patent applications. Iterum The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 14.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. For clarity, Iterum shall be free to publish and present all Developed IP generated by or on behalf of Iterum or its Affiliates or Partners under this Agreement without Pfizer’s review or approval (unless this Agreement has been terminated in any country or countries by Pfizer pursuant to Section 13.2 or by Iterum pursuant to Section 13.4, in which case Iterum shall obtain Pfizer’s prior written consent before such publication or presentation according to the procedures set forth in this Section 14.3 for publication or presentation of Pfizer Confidential Information)6.3.2.